Quick Answer
Atea Pharmaceuticals, Inc. reported Revenue (ASC 606) of $351.37 million for fiscal year 2021.
Atea Pharmaceuticals, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2021 | $351.37M | +622.5% |
| 2020 | $48.63M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2021 | $32.81M | — | -45.7% |
| June 30, 2021 | $60.39M | — | -8.5% |
| March 31, 2021 | $65.98M | — | — |
- Atea Pharmaceuticals, Inc. showed an increase of +622.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2020–2021 period, Atea Pharmaceuticals, Inc.’s revenue (asc 606) has grown by 622.5% (from $48.63 million to $351.37 million).
- The most recent figure is from Atea Pharmaceuticals, Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on February 28, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: